Treatment of diabetic rats with either SGLT2i (dapagliflozin) or GLP1 (liraglutide) protected the hearts from DCM, and SGLT2i offered more cardioprotective effects than GLP1. The gene discussed is GCG; the disease is familial dilated cardiomyopathy.